These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 23293520)

  • 21. Liposomes as nanovaccine delivery systems.
    Ghaffar KA; Giddam AK; Zaman M; Skwarczynski M; Toth I
    Curr Top Med Chem; 2014; 14(9):1194-208. PubMed ID: 24678703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
    Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
    J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
    Gao W; Xiang B; Meng TT; Liu F; Qi XR
    Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted anticancer therapy: overexpressed receptors and nanotechnology.
    Akhtar MJ; Ahamed M; Alhadlaq HA; Alrokayan SA; Kumar S
    Clin Chim Acta; 2014 Sep; 436():78-92. PubMed ID: 24836529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
    Chen Z; Deng J; Zhao Y; Tao T
    Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal nanomedicines in the treatment of prostate cancer.
    Kroon J; Metselaar JM; Storm G; van der Pluijm G
    Cancer Treat Rev; 2014 May; 40(4):578-84. PubMed ID: 24216226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
    Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
    J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using Properties of Tumor Microenvironments for Controlling Local, On-Demand Delivery from Biopolymer-Based Nanocarriers.
    Alshememry AK; El-Tokhy SS; Unsworth LD
    Curr Pharm Des; 2017; 23(35):5358-5391. PubMed ID: 28530543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future directions of liposome- and immunoliposome-based cancer therapeutics.
    Park JW; Benz CC; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting.
    Lohade AA; Jain RR; Iyer K; Roy SK; Shimpi HH; Pawar Y; Rajan MG; Menon MD
    AAPS PharmSciTech; 2016 Dec; 17(6):1298-1311. PubMed ID: 26689406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming barriers by local drug delivery with liposomes.
    Antimisiaris SG; Marazioti A; Kannavou M; Natsaridis E; Gkartziou F; Kogkos G; Mourtas S
    Adv Drug Deliv Rev; 2021 Jul; 174():53-86. PubMed ID: 33539852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis.
    Doppalapudi S; Jain A; Chopra DK; Khan W
    Eur J Pharm Sci; 2017 Jan; 96():515-529. PubMed ID: 27777066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal nanostructures for photosensitizer delivery.
    Jin CS; Zheng G
    Lasers Surg Med; 2011 Sep; 43(7):734-48. PubMed ID: 22057501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulus-responsive nanoscale delivery systems triggered by the enzymes in the tumor microenvironment.
    Zhang ZT; Huang-Fu MY; Xu WH; Han M
    Eur J Pharm Biopharm; 2019 Apr; 137():122-130. PubMed ID: 30776412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-functional vesicles for cancer therapy: The ultimate magic bullet.
    Tavano L; Muzzalupo R
    Colloids Surf B Biointerfaces; 2016 Nov; 147():161-171. PubMed ID: 27500359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomes, new carriers for delivery of genes and anticancer drugs: a systematic review.
    Salari N; Rasoulpoor S; Valipour E; Mansouri K; Bartina Y; Dokaneheifard S; Mohammadi M; Abam F
    Anticancer Drugs; 2022 Jan; 33(1):e9-e20. PubMed ID: 34282743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ligand nanoparticle conjugation approach for targeted cancer therapy.
    Karra N; Benita S
    Curr Drug Metab; 2012 Jan; 13(1):22-41. PubMed ID: 21892918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft.
    Chaudhury A; Das S; Bunte RM; Chiu GN
    Int J Nanomedicine; 2012; 7():739-51. PubMed ID: 22359453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
    McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
    Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted liposomal drug delivery: a nanoscience and biophysical perspective.
    Liu Y; Castro Bravo KM; Liu J
    Nanoscale Horiz; 2021 Feb; 6(2):78-94. PubMed ID: 33400747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.